RNAi Digest - August 2020

RNAi Digest - August 2020

Vir Biotechnology, Alnylam, Arrowhead, BMS, Novartis, Janssen reported results from their respective RNAi based therapies at key medical congresses

The Digital International Liver Congress – The Annual Meeting of the European Association for the Study of the Liver (EASL): 27 – 29 August, 2020

CompanyAssetOral presentationsPoster presentations
Vir Biotechnology/ Alnylam PharmaceuticalVIR-2218 (siRNA, HBV)
  • Top-line results from ongoing Phase 2 study
  • First in human Phase 1 data
  • In vitro, in vivo data
  • New data on ESC+ technology
Arrowhead Pharmaceutical/ JanssenJNJ-3989 (siRNA, HBV)
  • Late breaking: Interim 24 week data from Phase 2 JADE study
Alnylam PharmaceuticalGivosiran (siRNA, Acute hepatic porphyria)
  • 12 month interim results from ENVISION open label extension study
BMSBMS-986263 (siRNA, Hepatic fibrosis)–
  • Late breaking: Week 36 results from Phase 2 study

European Society of Cardiology (ESC) Congress 2020 The Digital Experience: 29 August – 01 September, 2020

CompanyAssetOral presentationsPoster presentations
Arrowhead PharmaceuticalARO-ANG3 (TRiM, Hypolipidemia)–
Arrowhead PharmaceuticalARO-APOC3 (TRiM, Apolipoprotein C-III deficiency)
  • Initial results from Phase 1 study: Healthy subjects, Apolipoprotein C-III deficiency patients
–
NovartisInclisiran (siRNA, Statin intolerance)–

Abstract links: EASL, ESC

Home